KTRA TuHURA Biosciences, Inc./NV

Nasdaq tuhurabio.com


$ 2.53 $ 0.03 (1.19 %)    

Wednesday, 15-Oct-2025 17:53:39 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 2.56
$ 2.54
$ 2.47 x 1,000
$ 2.66 x 799
$ 2.50 - $ 2.62
$ 1.80 - $ 292.04
196,379
na
4.29M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 10-07-2024 06-30-2024 10-K
6 05-14-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 09-18-2023 06-30-2023 10-K
10 05-11-2023 03-31-2023 10-Q
11 02-14-2023 12-31-2022 10-Q
12 11-09-2022 09-30-2022 10-Q
13 09-27-2022 06-30-2022 10-K
14 05-13-2022 03-31-2022 10-Q
15 02-11-2022 12-31-2021 10-Q
16 11-15-2021 09-30-2021 10-Q
17 09-28-2021 06-30-2021 10-K
18 05-13-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-Q
20 11-12-2020 09-30-2020 10-Q
21 09-18-2020 06-30-2020 10-K
22 05-13-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-Q
24 11-13-2019 09-30-2019 10-Q
25 09-09-2019 06-30-2019 10-K
26 05-14-2019 03-31-2019 10-Q
27 02-11-2019 12-31-2018 10-Q
28 11-13-2018 09-30-2018 10-Q
29 09-24-2018 06-30-2018 10-K
30 05-15-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-Q
32 11-09-2017 09-30-2017 10-Q
33 09-27-2017 06-30-2017 10-K
34 05-12-2017 03-31-2017 10-Q
35 02-10-2017 12-31-2016 10-Q
36 11-10-2016 09-30-2016 10-Q
37 09-13-2016 06-30-2016 10-K
38 05-12-2016 03-31-2016 10-Q
39 02-12-2016 12-31-2015 10-Q
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kintara-therapeutics-announces-record-date-for-contingent-value-rights-issuance-in-connection-with-the-proposed-merger-with-tuhura-biosciences-expected-to-close-on-october-18-2024

 Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new so...

 kintara-therapeutics-2024-eps-032-up-from-927-yoy-cash-and-cash-equivalents-49m

Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the...

 kintara-therapeutics-provides-update-on-rem-001-clinical-study-has-enrolled-4-of-the-10-patients-needed-to-reach-the-minimum-patient-enrollment-to-assess-safety-and-appropriate-phase-3-dose-with-several-other-patients-identified-as-study-candidates-at-kintaras-clinical-sites-no-treatment-related-safety-issues-have-been-identified-to-date-and-assessment-of-the-appropriate-phase-3-dose-is-ongoing

REM-001 Clinical Study UpdateAs of September 10, 2024, the REM-001 study in patients with cutaneous metastatic breast cancer (C...

 kintara-therapeutics-to-hold-special-meeting-for-completion-of-proposed-merger-with-tuhura-biosciences

Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count

Core News & Articles

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel t...

 tuhura-biosciences-and-kintara-therapeutics-announce-phase-1b-trial-of-ifx-20-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-and-cutaneous-squamous-cell-carcinoma-results

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION